Infinity to Present At Upcoming Conferences
September 02, 2009 07:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 2, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that management will...
Infinity Reports Recent R&D Highlights and Second Quarter 2009 Results
August 05, 2009 16:15 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 5, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today reviewed recent R&D highlights,...
Infinity Announces Second Quarter 2009 Results Conference Call
July 30, 2009 06:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 30, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced today that Infinity management...
Infinity Paper On Discovery of Its Novel Hedgehog Inhibitor, IPI-926, Published in Journal of Medicinal Chemistry
July 23, 2009 16:40 ET
|
Infinity Pharmaceuticals, Inc.
-- Paper Features Chemistry and Preclinical Data Leading to
Discovery of IPI-926 - Currently in Phase 1 Development --
-- Publication Follows Recent Paper in Science Demonstrating
...
Infinity Pharmaceuticals Added to Russell 2000(r) Index
June 29, 2009 06:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 29, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it was added to the...
Infinity Reports Encouraging Clinical Data for IPI-504 at ASCO 2009
May 30, 2009 14:00 ET
|
Infinity Pharmaceuticals, Inc.
Phase 2 Data Show Partial Responses and Generally Well-Tolerated
Safety Profile in Patients with Advanced Non-Small Cell Lung Cancer
Phase 1 Study Demonstrates Combinability of IPI-504...
New Paper in Science Features Infinity's IPI-926 Hedgehog Pathway Inhibitor as a Promising New Approach in Chemo-Resistant Pancreatic Cancer
May 29, 2009 06:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 29, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced the recent publication of a new...
Infinity Pharmaceuticals Named Winner of The Scientist's 'Best Places to Work in Industry' and Featured in Boston Business Journal's Best Places to Work 2009 Survey
May 27, 2009 13:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 27, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it has been named one...
Clinical Data From Infinity's Hsp90 Chaperone Inhibitor Program to be Presented During ASCO Meeting
May 13, 2009 07:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 13, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it will be reporting...
Infinity Reports Recent Pipeline Developments and First Quarter 2009 Results
May 04, 2009 16:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 4, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today reviewed recent clinical...